single20MG
Vilon
20MG Protocol
Vilon 20MG
Injection Freq.
Once per day (subcutaneous) for 5 consecutive days per cycle
Cycle Sched.
5 days on, ~23 days off (4‑week cycle); run 2–4 cycles
Reconstitution
3.0 mL BAC water
Supports immune-marker and cytokine-gene activity in cell-culture models (CD5+, IL-2)
Potential modulation of inflammatory signaling pathways in preclinical renal models
Early mouse studies referenced suggest tumor-growth inhibition and lifespan-extension signals (limited human relevance)
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1+ | 67 mcg (0.067 mg) | 1 |
| 2 | Weeks 1+ | 133 mcg (0.133 mg) | 2 |
| 3 | Weeks 1+ | 200 mcg (0.20 mg) | 3 |
| 4 | Weeks 1+ | 267 mcg (0.267 mg) | 4 |
| 5 | Weeks 1+ | 333 mcg (0.33 mg) | 5 |
| 6 | Weeks 1+ | 333–667 mcg (0.33–0.67 mg) | 10 |
Once per day (subcutaneous) for 5 consecutive days per cycle
5 days on, ~23 days off (4‑week cycle); run 2–4 cycles
Vilon (Lys–Glu) is presented as a short ‘bioregulatory’ peptide developed in the context of Russian gerontology research. The protocol’s mechanism section emphasizes in vitro immunomodulatory findings rather than a single receptor target. Specifically, Vilon is described as influencing lymphocyte markers and cytokine gene expression: studies cited on the page report increased CD5+ cell counts in thymus cell cultures and increased interleukin-2 (IL-2) mRNA expression in splenocyte preparations. Additional preclinical observations referenced include potential effects on inflammatory signaling (e.g., TGF-β1) and vascular permeability in renal models under experimental stress. The protocol also explains its pulsed schedule (a short 5-day series repeated on a monthly cycle) as analogous to other short-peptide regimens used in related research traditions. Overall, Vilon is positioned as an investigational immune-signaling modulator with limited direct human clinical characterization.
Mild injection-site reactions (redness/itching)
Limited human clinical data
evidence base described as preclinical/in vitro
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)